Treatment with ipatasertib plus paclitaxel in the first-line setting demonstrated a trend toward improved overall survival (OS) compared with paclitaxel alone in women with inoperable locally advanced/metastatic triple-negative breast cancer (TNBC), according to final results of the phase II LOTUS trial.
Adding veliparib to a carboplatin-paclitaxel combination improved progression-free survival (PFS) in patients with BRCA1/2 hormone receptor-positive (HR+) or triple-negative breast cancer (TNBC), subgroup analysis of the phase III BROCADE3* trial showed.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.